background
role
airway
microbiom
develop
recurr
wheez
asthma
remain
uncertain
particularli
highrisk
group
infant
hospit
bronchiol
object
sought
examin
relat
nasal
microbiota
bronchiolitisrel
hospit
later
point
risk
recurr
wheez
age
year
method
us
center
research
collect
clinic
data
nasal
swab
infant
hospit
bronchiol
train
parent
collect
nasal
swab
week
hospit
healthi
summer
year
hospit
appli
rrna
gene
sequenc
nasal
swab
use
joint
model
examin
relat
longitudin
nasal
microbiota
abund
risk
recurr
wheez
result
among
infant
hospit
bronchiol
followup
year
recurr
wheez
median
age
enrol
month
interquartil
rang
month
joint
model
analys
adjust
covari
includ
viral
caus
increas
rel
abund
moraxella
streptococcu
speci
week
day
hospit
associ
increas
risk
recurr
wheez
hazard
ratio
hr
highdens
interv
hdi
hr
hdi
respect
increas
streptococcu
speci
abund
summer
hospit
also
associ
greater
risk
recurr
wheez
hr
hdi
conclus
enrich
moraxella
streptococcu
speci
bronchiol
hospit
associ
recurr
wheez
age
year
possibl
provid
new
avenu
amelior
longterm
respiratori
outcom
infant
sever
bronchiol
j
allergi
clin
immunol
increas
moraxella
streptococcu
speci
abund
sever
bronchiol
associ
recurr
wheez
bronchiol
acut
respiratori
tract
infect
lead
caus
hospit
us
infant
account
approxim
hospit
annual
addit
acut
sever
ill
hospit
infant
time
like
healthi
control
subject
recurr
wheez
childhood
asthma
unfortun
infant
longterm
respiratori
morbid
bronchiol
hospit
remain
incomplet
defin
date
longitudin
bronchiol
cohort
studi
use
common
viral
caus
bronchiol
respiratori
syncyti
viru
rsv
rhinoviru
primari
exposur
howev
respiratori
tract
virus
infect
infant
airway
colon
highli
function
bacteria
emerg
evid
suggest
bacteri
composit
airway
associ
acut
sever
outcom
also
longterm
respiratori
outcom
decad
ago
bisgaard
et
al
use
convent
cultur
report
hypopharyng
colon
moraxella
haemophilu
streptococcu
speci
asymptomat
infant
associ
recurr
wheez
childhood
asthma
recent
crosssect
cultureindepend
studi
shown
compar
healthi
control
subject
children
adult
asthma
airway
microbiota
composit
enrich
proteobacteria
eg
moraxella
haemophilu
speci
furthermor
longitudin
microbiota
studi
first
year
life
found
moraxella
haemophilu
streptococcu
speci
domin
nasopharyng
commun
acut
respiratori
tract
infect
sensit
children
associ
chronic
wheez
age
year
abbrevi
use
hdi
highdens
interv
hr
hazard
ratio
multicent
airway
research
collabor
npa
nasopharyng
aspir
rsv
respiratori
syncyti
viru
date
howev
studi
examin
multicent
cohort
infant
hospit
bronchiol
associ
longitudin
composit
nasal
microbiota
risk
recurr
wheez
childhood
inde
first
longitudin
microbiota
analysi
present
cohort
hypothes
posthospit
increas
moraxella
speci
rel
abund
associ
greater
risk
recurr
wheez
age
year
previous
describ
site
team
hospit
us
state
enrol
infant
age
year
hospit
bronchiol
multicent
airway
research
collabor
http
wwwemnetusaorg
attend
physician
diagnos
infant
bronchiol
base
american
academi
pediatr
definit
enrol
occur
consecut
winter
season
ie
novemberapril
institut
review
board
particip
hospit
approv
studi
famili
sign
inform
consent
form
particip
research
team
site
extract
clinic
data
emerg
depart
inpati
chart
also
conduct
structur
interview
parentsleg
guardian
hospit
demograph
histor
environment
inform
site
research
collect
nasopharyng
aspir
npa
within
hour
hospit
use
equip
eg
sampl
trap
suction
cathet
medlin
industri
mundelein
ill
standard
protocol
previous
describ
nasal
swab
collect
within
hour
hospit
site
team
collect
index
nasal
swab
anterior
nare
use
singl
nylon
pediatr
floqswab
copan
brescia
itali
swab
collect
either
npa
collect
hour
npa
collect
hospit
site
team
taught
parent
collect
nasal
swab
sampl
possibl
index
sampl
collect
site
team
swab
nare
parent
practic
techniqu
swab
nare
three
week
date
hospit
use
sampl
collect
method
train
parent
collect
clearanc
swab
summer
june
juli
august
hospit
children
healthi
parent
collect
summer
swab
year
hospit
children
randomli
assign
specif
season
healthi
swab
collect
therefor
one
fourth
parent
assign
collect
season
swab
summer
june
juli
august
fall
septemb
octob
novemb
winter
decemb
januari
februari
spring
march
april
may
collect
swab
process
previous
describ
rrna
gene
sequenc
previous
describ
sequenc
rrna
gene
region
nasal
swab
bacteria
illumina
miseq
platform
illumina
san
diego
calif
use
microbiota
data
suffici
sequenc
depth
ie
read
per
sampl
analys
quantit
rtpcr
assay
use
npa
sampl
hospit
quantit
rtpcr
assay
conduct
baylor
colleg
medicin
previous
describ
virus
rsv
type
b
rhinoviru
influenza
type
b
novel
human
metapneumoviru
human
bocaviru
parainfluenza
virus
type
adenoviru
enteroviru
coronavirus
base
biannual
parent
telephon
interview
primari
outcom
present
analysi
recurr
wheez
age
year
defin
nation
institut
health
expert
panel
report
least
corticosteroidrequir
exacerb
month
least
wheez
episod
year
last
least
day
affect
sleep
requir
specifi
time
frame
episod
wheez
wheez
earli
childhood
transient
extend
outcom
children
recurr
wheez
age
year
also
asthma
age
year
defin
asthma
age
year
use
epidemiolog
definit
physician
diagnosi
asthma
either
asthma
medic
use
eg
albuterol
inhal
inhal
corticosteroid
asthmarel
symptom
eg
wheez
nocturn
cough
age
year
analys
includ
subject
index
microbiota
sampl
suffici
qualiti
microbiota
sampl
collect
onset
recurr
wheez
exclud
maintain
consist
crosssect
longitudin
timetoev
analys
covari
patient
characterist
clinic
present
collect
index
visit
compar
children
without
recurr
wheez
use
x
wilcoxon
rank
sum
test
appropri
unrarefi
rrna
gene
sequenc
read
count
combin
genu
level
defin
top
genera
greatest
mean
rel
abund
across
sampl
kruskalw
rank
sum
test
assess
signific
differ
age
adivers
shannon
index
rel
abund
top
genera
across
time
point
p
valu
top
genera
comparison
determin
use
bonferroni
correct
multipl
test
examin
relat
genu
abund
recurr
wheez
first
perform
crosssect
analys
data
calcul
overal
mean
microbi
abund
genu
interest
use
rel
abund
across
time
point
base
microbi
abund
time
point
categor
nasal
sampl
group
greater
less
mean
x
test
determin
signific
associ
group
recurr
wheez
multipl
comparison
correct
use
analys
serv
exploratori
analys
joint
model
next
perform
longitudin
analys
construct
joint
model
longitudin
microbi
data
quantifi
relationship
onset
recurr
wheez
specif
creat
longitudin
mixedeffect
gener
linear
model
predict
rel
genu
abund
time
use
abund
taxa
clinic
covari
fix
effect
time
random
slope
subject
random
intercept
rel
abund
interact
time
point
scale
chang
abund
equival
unit
chang
incorpor
timedepend
covari
cox
proport
hazard
model
outcom
recurr
wheez
age
year
use
bayesian
method
modifi
version
rstanarm
r
packag
assum
scale
default
prior
distribut
bayesian
approach
produc
conserv
model
estim
without
multipl
comparison
problem
found
frequentist
approach
signific
determin
use
highdens
interv
hdi
posterior
distribut
log
hazard
ratio
hr
within
region
practic
equival
around
zero
confirm
joint
model
result
gener
kaplanmei
curv
stratifi
group
particip
identifi
joint
model
greater
risk
recurr
wheez
use
logrank
test
determin
statist
signific
also
conduct
joint
model
sensit
analysi
restrict
outcom
children
recurr
wheez
age
year
also
asthma
age
year
highrisk
group
identifi
use
joint
model
gener
local
weight
scatterplot
smooth
ie
loess
curv
ci
rel
abund
time
day
hospit
process
creat
smooth
curv
risk
group
repeat
includ
top
genera
remov
genera
show
impercept
chang
time
improv
clariti
use
rug
plot
sampl
time
instead
ci
indic
distribut
observ
overlap
particip
membership
risk
group
identifi
use
joint
model
assess
venn
diagram
remov
group
overlap
patient
characterist
clinic
present
compar
risk
group
use
fisher
exact
kruskalw
test
appropri
analysi
use
r
version
softwar
p
valu
p
valu
less
consid
statist
signific
infant
longitudin
cohort
suffici
sequenc
depth
ie
read
per
sampl
includ
present
analysi
analyt
nonanalyt
cohort
differ
antibiot
use
hospit
p
greater
percentag
infant
nonanalyt
cohort
use
antibiot
see
tabl
articl
onlin
repositori
wwwjacionlineorg
analyt
cohort
median
age
hospit
month
interquartil
rang
month
male
histori
wheez
character
bacteri
microbiota
use
nasal
swab
index
clearanc
summer
season
swab
collect
hospit
bronchiol
followup
age
year
overal
infant
recurr
wheez
age
year
tabl
summar
characterist
among
children
recurr
wheez
gener
infant
recurr
wheez
older
studi
entri
mother
asthma
person
histori
eczema
rsvneg
bronchiol
data
present
number
percentag
unless
otherwis
indic
p
valu
comput
use
x
test
categor
variabl
wilcoxon
rank
sum
test
continu
variabl
iqr
interquartil
rang
detect
npa
sampl
collect
index
visit
defin
detect
posit
valu
serum
allergenspecif
ige
index
visit
admiss
intens
care
unit
andor
use
mechan
ventil
continu
posit
airway
pressur
andor
intub
inpati
stay
regardless
locat
time
index
hospit
median
age
time
nasal
swab
collect
shannon
index
score
abund
top
nasal
microbiota
genera
swab
collect
time
point
shown
tabl
articl
onlin
repositori
wwwjacionlineorg
nasal
swab
collect
continu
median
age
month
adivers
lowest
clearanc
time
point
greatest
season
time
point
among
genera
interest
moraxella
haemophilu
streptococcu
speci
top
genera
rel
abund
rel
abund
moraxella
haemophilu
streptococcu
speci
time
point
risk
recurr
wheez
age
year
crosssect
analys
hospit
found
rel
abund
risk
bacteria
ie
moraxella
haemophilu
streptococcu
speci
associ
recurr
wheez
age
year
contrast
clearanc
time
point
ie
week
day
hospit
infant
rel
abund
moraxella
speci
greater
mean
significantli
greater
risk
recurr
wheez
age
year
infant
rel
abund
less
mean
p
fig
parallel
analys
associ
haemophilu
speci
abund
recurr
wheez
reach
signific
time
point
see
fig
articl
onlin
repositori
wwwjacionlineorg
howev
infant
streptococcu
speci
abund
greater
mean
either
clearanc
summer
time
point
significantli
greater
risk
recurr
wheez
age
year
compar
infant
less
mean
streptococcu
speci
abund
p
p
respect
fig
b
longitudin
moraxella
haemophilu
streptococcu
speci
abund
hospit
hazard
recurr
wheez
age
year
aforement
crosssect
result
also
shown
longitudin
analysi
use
joint
model
joint
model
increas
moraxella
speci
rel
abund
clearanc
time
point
associ
develop
recurr
wheez
age
year
adjust
confound
matern
asthma
birth
mode
histori
eczema
sensit
viral
caus
intens
care
use
hr
hdi
fig
thu
everi
increas
abund
moraxella
speci
clearanc
time
point
increas
risk
recurr
wheez
age
year
similar
crosssect
analys
haemophilu
speci
abund
reach
signific
joint
model
analys
see
fig
contrast
found
increas
streptococcu
speci
abund
clearanc
time
point
summer
hospit
associ
recurr
wheez
age
year
hr
hdi
hr
hdi
respect
fig
sensit
analys
creat
kaplanmei
curv
stratifi
risk
group
ie
increas
moraxella
speci
abund
clearanc
time
point
increas
streptococcu
speci
abund
clearanc
time
point
increas
streptococcu
speci
abund
summer
time
point
identifi
crosssect
joint
model
analys
fig
surviv
analys
demonstr
increas
hazard
recurr
wheez
age
year
infant
high
moraxella
streptococcu
speci
abund
clearanc
time
point
p
high
streptococcu
speci
abund
summer
time
point
p
longitudin
moraxella
streptococcu
speci
abund
hospit
among
children
recurr
wheez
age
year
also
asthma
age
year
address
potenti
heterogen
recurr
wheez
examin
children
recurr
wheez
age
year
also
asthma
age
year
support
recurr
wheez
result
found
joint
model
children
greater
moraxella
streptococcu
speci
abund
clearanc
time
point
increas
risk
recurr
wheez
accompani
asthma
age
year
hr
hdi
hr
hd
respect
fig
children
increas
streptococcu
speci
abund
summer
time
point
borderlin
signific
increas
risk
recurr
wheez
asthma
age
year
hr
hdi
fig
nasal
microbiota
risk
group
increas
moraxella
speci
abund
clearanc
time
point
increas
streptococcu
speci
abund
clearanc
time
point
increas
streptococcu
speci
abund
summer
time
point
minim
overlap
see
fig
articl
onlin
repositori
wwwjacionlineorg
compar
characterist
clinic
present
infant
within
risk
group
exclud
infant
risk
group
found
children
increas
moraxella
streptococcu
speci
abund
clearanc
time
point
wheez
hospit
children
increas
streptococcu
speci
abund
summer
time
point
otherwis
risk
group
similar
demograph
clinic
present
see
tabl
articl
onlin
repositori
wwwjacionlineorg
also
found
increas
abund
found
risk
group
present
subsequ
sampl
time
point
examin
whether
transient
natur
increas
abund
could
due
antibiot
administr
found
patient
receiv
antibiot
either
hospit
accord
current
bronchiol
practic
guidelin
moreov
signific
differ
antibiot
administr
patient
taxa
abund
greater
less
mean
see
tabl
articl
onlin
repositori
wwwjacionlin
org
prospect
multicent
cohort
infant
hospit
bronchiol
identifi
crosssect
surviv
joint
model
analys
increas
rel
abund
nasal
moraxella
streptococcu
speci
week
day
hospit
increas
nasal
streptococcu
speci
abund
summer
hospit
associ
recurr
wheez
age
year
data
corrobor
relat
infant
moraxella
streptococcu
speci
abund
childhood
wheez
outcom
extend
prior
research
focus
highrisk
cohort
infant
hospit
bronchiol
also
analyz
hospit
posthospit
sampl
use
robust
longitudin
analyt
techniqu
ie
joint
model
although
replic
need
causal
establish
might
identifi
infant
hospit
bronchiol
short
window
opportun
ie
week
hospit
influenc
secondari
success
nasal
microbi
ecosystem
potenti
risk
recurr
wheez
age
year
recurr
wheez
accompani
asthma
age
year
past
year
multipl
cohort
studi
demonstr
infant
hospit
bronchiol
recurr
wheez
within
year
hospit
furthermor
compar
healthi
control
subject
children
hospit
bronchiol
also
much
greater
risk
childhood
asthma
even
longerterm
respiratori
morbid
mani
bronchiol
cohort
focus
viral
infect
eg
rsv
howev
virus
infect
infant
within
complex
microbi
ecosystem
ie
microbiom
research
result
last
decad
demonstr
airway
bacteria
includ
nasal
microbiota
also
associ
wheez
outcom
children
sever
studi
airway
microbiota
implic
moraxella
haemophilu
andor
streptococcu
speci
risk
bacteria
wheez
asthma
use
crosssect
prospect
studi
design
teo
et
al
found
australian
childhood
asthma
studi
n
asymptomat
nasopharyng
colon
high
abund
streptococcu
speci
around
age
month
associ
wheez
age
year
cohort
greater
frequenc
detect
nasopharyng
moraxella
haemophilu
streptococcu
speci
time
health
age
month
year
associ
sensit
children
n
greater
odd
chronic
wheez
age
year
nonsensit
children
n
wheez
first
year
life
ie
transient
wheez
first
time
examin
longitudin
nasal
abund
risk
bacteria
ie
moraxella
haemophilu
streptococcu
speci
larg
divers
multicent
cohort
us
infant
hospit
bronchiol
rel
abund
risk
bacteria
hospit
associ
recurr
wheez
age
year
howev
week
sever
viral
infect
enrich
infant
nasal
ecosystem
either
moraxella
streptococcu
speci
increas
risk
recurr
wheez
age
year
kaplanmei
curv
gener
risk
group
outcom
recurr
wheez
age
year
curv
stratifi
membership
risk
group
tabl
show
number
subject
still
risk
recurr
wheez
base
event
occurr
studi
dropout
infant
includ
risk
group
logrank
test
result
indic
differ
hazard
function
stratifi
curv
signific
risk
group
j
allergi
clin
immunol
volum
number
recurr
wheez
accompani
asthma
age
year
similar
childhood
asthma
studi
also
found
separ
group
children
median
age
month
ie
around
month
hospit
although
healthi
increas
streptococcu
speci
abund
greater
risk
recurr
wheez
age
year
howev
remain
unclear
infant
later
increas
streptococcu
speci
abund
seen
fig
later
onset
recurr
wheez
lack
signific
associ
haemophilu
speci
might
due
inadequ
power
weaker
associ
importantli
confirm
find
use
multipl
analyt
techniqu
moreov
joint
model
demonstr
present
microbiota
find
independ
multipl
potenti
confound
factor
associ
childhood
asthma
includ
viral
caus
ige
sensit
infanc
find
suggest
intervent
alter
nasal
microbiom
hospit
bronchiol
might
benefici
inde
beigelman
et
al
found
small
n
random
placebocontrol
trial
azithromycin
day
infant
hospit
rsvrelat
bronchiol
reduc
nasal
lavag
moraxella
speci
abund
week
furthermor
concord
find
decreas
moraxella
speci
abund
day
matter
group
assign
associ
reduc
odd
recurr
wheez
ie
wheez
episod
subsequ
month
potenti
approach
bronchiol
treatment
need
studi
thought
consider
possibl
unintend
consequ
widespread
antibiot
use
inde
bronchiol
longterm
respiratori
outcom
might
best
understood
complex
adapt
system
taken
togeth
potenti
health
effect
airway
microbiom
tantal
howev
note
earli
moraxella
speci
colon
healthi
infant
associ
lower
rate
respiratori
tract
infect
thu
understand
potenti
protect
role
moraxella
speci
healthi
popul
compar
consist
identif
risk
bacterium
acut
respiratori
tract
infect
also
asthmat
patient
critic
advanc
understand
role
genu
ultim
strain
moraxella
speci
respiratori
condit
also
possibl
posthospit
increas
moraxella
streptococcu
speci
abund
might
simpli
marker
children
alreadi
predispos
recurr
wheez
altern
associ
posthospit
increas
moraxella
streptococcu
speci
abund
recurr
wheez
might
causal
ie
microbiota
might
influenc
host
immun
respons
viral
infect
true
influenc
microbiom
reassembl
hospit
bronchiol
either
antibiot
prefer
intranas
administr
protect
speci
might
approach
help
prevent
asthma
highrisk
group
studi
potenti
limit
first
although
bronchiol
lead
caus
hospit
infant
suggest
caution
gener
result
beyond
approxim
us
infant
hospit
bronchiol
year
second
bronchiol
condit
affect
entir
airway
nose
lung
although
sampl
nose
might
repres
pathobiolog
lung
nasal
bronchial
cell
similar
respons
stimul
signific
mediat
releas
correl
third
healthi
control
group
studi
object
examin
associ
microbiom
develop
bronchiol
within
gener
popul
rather
determin
relat
nasal
microbiota
recurr
wheez
within
highrisk
popul
infant
hospit
bronchiol
fourth
although
followup
age
year
number
nasal
swab
includ
analys
decreas
time
parent
forget
collect
swab
exclus
sampl
collect
onset
recurr
wheez
requir
joint
model
fifth
present
result
unabl
untangl
host
environment
condit
includ
bacterialbacteri
interact
time
infect
might
enhanc
surviv
certain
speci
howev
group
current
examin
role
airway
microbehost
relat
develop
childhood
asthma
sixth
analys
need
repeat
children
cohort
turn
year
age
formal
evalu
asthma
final
present
analysi
account
neither
potenti
genet
differ
within
sampl
differ
strain
moraxella
streptococcu
speci
microbiom
function
current
pursu
import
research
question
summari
identifi
larg
prospect
multicent
cohort
divers
us
infant
hospit
bronchiol
increas
abund
nasal
moraxella
streptococcu
speci
week
month
hospit
relat
recurr
wheez
age
year
result
confirm
moraxella
streptococcu
speci
risk
bacteria
also
identifi
potenti
window
opportun
clinician
amelior
chronic
respiratori
outcom
highrisk
group
children
inde
find
might
serv
start
point
begin
investig
would
chang
manag
common
pediatr
condit
proven
effect
intervent
beyond
support
care
b
increas
streptococcu
speci
abund
clearanc
time
point
n
c
increas
streptococcu
speci
abund
summer
time
point
n
infant
classifi
risk
group
use
mean
cutoff
moraxella
mean
streptococcu
mean
speci
abund
relev
time
point
might
includ
risk
group
rug
plot
along
xaxi
denot
distribut
observ
time
subject
specifi
risk
group
acinetobact
bacillu
speci
abund
notic
variat
time
exclud
improv
readabl
data
present
number
percentag
unless
otherwis
indic
p
valu
comput
use
x
test
categor
variabl
wilcoxon
rank
sum
test
continu
variabl
kruskalw
rank
sum
test
rel
abund
iqr
interquartil
rang
one
index
swab
lost
shipment
detect
npa
sampl
collect
index
visit
detect
posit
valu
serum
allergenspecif
ige
index
visit
food
allergen
aeroallergen
admiss
intens
care
unit
andor
use
mechan
ventil
continu
posit
airway
pressur
andor
intub
inpati
stay
regardless
locat
time
index
hospit
data
present
number
percentag
unless
otherwis
indic
subject
risk
group
exclud
p
valu
comput
use
fisher
exact
test
categor
variabl
wilcoxon
rank
sum
test
continu
variabl
iqr
interquartil
rang
rv
rhinoviru
detect
npa
sampl
collect
index
visit
defin
detect
posit
valu
serum
allergenspecif
ige
index
visit
food
allergen
aeroallergen
admiss
intens
care
unit
andor
use
mechan
ventil
continu
posit
airway
pressur
andor
intub
inpati
stay
regardless
locat
time
index
hospit
data
present
number
percentag
p
valu
comput
use
x
test
